Since loss of dopamine results in overactivity of the indirect pathway, A2AR antagonists have been proposed as therapeutic drugs for the treatment of Parkinson’s disease [75,145,146,147,148,149]. This evidence concerns the gene ADORA2A and Parkinson disease.